Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$42.14
−$0.91 · -2.11%
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Latest quote
$42.14
−$0.91 · -2.11%
After-hours
$42.14
$0.00 · 0.00%
Oct 8, 5:46 PM ET
Regular session · ET · Market data may be delayed.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Day range
Current $42.14
52-week range
Current $42.14
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
26
Expensive
Sentiment
48
Mixed
Risk
31
Moderate Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Day range
Current $42.14
52-week range
Current $42.14
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 718.95M USD | 661.82M USD | 607.52M USD | 667.24M USD | 579.78M USD |
| Cost of goods sold | 74.56M USD | 77.91M USD | 83.78M USD | 87.22M USD | 75.06M USD |
| Gross profit | 644.39M USD | 583.91M USD | 523.74M USD | 580.02M USD | 504.71M USD |
| Research and development | 106.24M USD | 108.8M USD | 91.59M USD | 74.55M USD | 90.47M USD |
| Selling, general, and administrative | 485.56M USD | 335.78M USD | 336.36M USD | 377.22M USD | 304.76M USD |
| Operating expenses | 681.25M USD | 502.25M USD | 529.01M USD | 533.89M USD | 418.69M USD |
| Interest income | 13.25M USD | 16.2M USD | 10.45M USD | 21.69M USD | 10.57M USD |
| Interest expense | — | — | 2.42M USD | 7.07M USD | 23.42M USD |
| Depreciation and amortization | 91.56M USD | 80.41M USD | 84.86M USD | 85.54M USD | 32.6M USD |
| Operating income | −36.86M USD | 81.67M USD | −5.27M USD | 46.12M USD | 86.03M USD |
| Net income | −38.55M USD | 73.87M USD | 1.32M USD | 60.71M USD | 53.42M USD |
Company facts updated Oct 8, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR149.58M0.15%104.29B USD0.06%$137.31+0.17%
Vanguard Morningstar Total Stock Market ETFVTI77.64M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM63.12M0.08%78.56B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB56M0.03%185.3B USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Value ETFVBR35.62M0.05%68.2B USD0.05%$233.91+0.75%
Vanguard Extended Market ETFVXF29.76M0.03%95.4B USD0.05%$233.13-0.15%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM23.34M0.15%16.01B USD0.03%$53.36+0.15%
Dimensional - US Small Cap ETFDFAS19.69M0.06%33.66B USD0.31%$78.10+0.23%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
